2024-05-11

International Conference 及2024 BIO International Convention

Shanghai, China, May 11, 2024 - Shanghai Novamab Biopharmaceuticals Co., Ltd., a biotechnology company dedicated to the research and development of innovative nanobody drugs, announced that Dr. Yakun

More

2024-04-23

Novamab: LQ036 Completes The First Patient Dosing in Phase IIa Clinical Study
— The First Inhaled Biological Agent in China Provides A New Treatment Option for Asthma Patients

Shanghai, China, April 23, 2024- Novamab, a biotechnology company dedicated to the research and development of innovative Nanobody drugs, announced that its core product LQ036 (an IL-4Rα single-domain

More

2024-03-05

BioCon 2024- "Research Progress of Inhalable Nanobody Drug Therapy for Asthma" A Brief Discussion on Differentiated Development of Antibody Drugs and Clinical Progress of Novamab

Beijing time, March 6, 2024 (Wednesday), from 19:45 to 20:25, Dr. Siran Pei, the head of Translational Medicine and Clinical Development at Novamab, will participate in the pre-event live broadcast of

More

2024-02-29

Research Information - The development and scaling up of the production process of Novamab‘s anti TSLP Nanobody have reached an internationally leading level

Shanghai, February 29, 2024 - Novamab, a biotechnology company dedicated to the research and development of innovative Nanobody drugs, announced the research progress on the development and scaling up

More

2024-02-22

Clinical Research Updatate - Novamab Announced the Latest Results of the Phase Ia Clinical Study on Inhaled TSLP Nanobody Drug LQ043H in Healthy Chinese Subjects

Shanghai, February 22, 2024- Novamab, a biotechnology company dedicated to the research and development of innovative Nonobody drugs, announced today the results of the tolerance, safety, pharmacokine

More

2023-12-19

Shanghai Novamab Biology, the world's first inhaled nanobody enterprise, has completed a round B financing of more than 100 million yuan

On December 18,2023, Shanghai Novamab Biopharmaceuticals Co., Ltd. (hereinafter referred to as: "Company or Novamab") successfully completed completed a Series B financing of over 100 million CNY.

More

2023-11-13

The research results of Novamab TROP2-ADC were published in the Journal of Nanobiotechnology!

Recently, Novamab and the team of Professor Zhang Xuyao/Ju Dianwen from the School of Pharmacy, Fudan University, jointly reported that the nanobody-drug conjugate (NDC) molecule targeting TROP2 has p

More

2023-09-26

Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference

Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference

More

2023-09-18

CDE approves IND application for LQ036 in the treatment of COPD

CDE approves IND application for LQ036 in the treatment of COPD ◇———A global leading Biotech in the  R&D of innovative Nanobody drugs———◇

More

2023-07-04

CEO of Novamab delivered a wonderful speech at the ACCESS CHINA Boston Forum

CEO of Luoqi Biotechnology delivers a speech at the ACCESS CHINA Pharmaceuticals China Boston ForumA leading global enterprise in the research and development of innovative nano antibody drugsThe offl

More